『Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill』のカバーアート

Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

無料で聴く

ポッドキャストの詳細を見る

概要

 In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
まだレビューはありません